SUMMARY
# Blood-Based Biomarker Panel for Early AD Detection
## Background and Rationale
Alzheimer's disease (AD) diagnosis currently relies on costly neuroimaging and invasive cerebrospinal fluid analysis, limiting early detection capabilities. This study addresses the critical need for accessible, blood-based biomarkers that can identify AD pathology before clinical symptoms manifest. The experiment leverages a multi-analyte approach, measuring established AD biomarkers including amyloid-β peptides (A
METHODOLOGY NOTES
Phase 1: Recruit 300 participants (100 cognitively normal controls, 100 MCI, 100 early AD) with confirmed amyloid PET status. Collect 10ml EDTA blood samples following 12-hour fasting. Phase 2: Process samples within 2 hours using standardized protocols. Separate plasma via centrifugation (2000g, 10 minutes, 4°C) and store at -80°C. Phase 3: Perform multiplex immunoassays using Simoa HD-X analyzer for Aβ40, Aβ42, p-tau181, p-tau217, NfL, and GFAP. Conduct ELISA for inflammatory markers (IL-6, TNF-α, CRP) and LC-MS/MS for metabolomic profiling. Phase 4: Culture SH-SY5Y cells and treat with 1μM Aβ42 oligomers for 24-48 hours. Collect conditioned media and measure biomarker release using identical assays. Phase 5: Apply machine learning algorithms (random forest, support vector machines, neural networks) to integrate biomarker data. Use 70% of samples for training, 30% for validation with 10-fold cross-validation. Phase 6: Develop composite diagnostic score and establish optimal cut-off v